We are live on ! Find out more
AIM

AIM ImmunoTech
AIM

31 hedge funds and large institutions have $2.05M invested in AIM ImmunoTech in 2023 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

23% more capital invested

Capital invested by funds: $1.67M → $2.05M (+$377K)

11% less funds holding

Funds holding: 35 → 31 (-4)

43% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 7

80% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 5

Holders
31
Holders Change
-4
Holders Change %
-11.43%
% of All Funds
0.49%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
4
Reduced
7
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$16.5K
2
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors
North Carolina
+$10.4K
3
BlackRock
BlackRock
New York
+$1.76K
4
TSS
Two Sigma Securities
New York
+$1.14K
5
TRCT
Tower Research Capital (TRC)
New York
+$881

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$159K
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$49.5K
3
BCM
Bridgeway Capital Management
Texas
-$21.9K
4
Citadel Advisors
Citadel Advisors
Florida
-$20.9K
5
UBS Group
UBS Group
Switzerland
-$15.2K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$855K – – –
BlackRock
2
BlackRock
New York
$351K +$1.76K +34 +0.4%
Morgan Stanley
3
Morgan Stanley
New York
$263K -$159K -3,064 -33%
Geode Capital Management
4
Geode Capital Management
Massachusetts
$164K – – –
State Street
5
State Street
Massachusetts
$74.4K – – –
Renaissance Technologies
6
Renaissance Technologies
New York
$73K +$16.5K +319 +23%
Verition Fund Management
7
Verition Fund Management
Connecticut
$61.9K -$4.72K -91 -6%
BCM
8
Bridgeway Capital Management
Texas
$46.8K -$21.9K -422 -28%
Northern Trust
9
Northern Trust
Illinois
$37.2K – – –
Rockefeller Capital Management
10
Rockefeller Capital Management
New York
$17K – – –
SWM
11
SeaCrest Wealth Management
New York
$15.9K – – –
Citadel Advisors
12
Citadel Advisors
Florida
$12.9K -$20.9K -403 -57%
Bank of New York Mellon
13
Bank of New York Mellon
New York
$10.9K – – –
T. Rowe Price Associates
14
T. Rowe Price Associates
Maryland
$9K -$49.5K -955 -82%
Cambridge Investment Research Advisors
15
Cambridge Investment Research Advisors
Iowa
$9K -$13.6K -263 -56%
FWM
16
ForthRight Wealth Management
Georgia
$8.6K – – –
CAPTRUST Financial Advisors
17
CAPTRUST Financial Advisors
North Carolina
$8.6K +$10.4K +200 New
TSS
18
Two Sigma Securities
New York
$7.14K +$1.14K +22 +15%
CB
19
Community Bank
New York
$5.69K – – –
TCM
20
Traynor Capital Management
Pennsylvania
$5.06K – – –
Susquehanna International Group
21
Susquehanna International Group
Pennsylvania
$4.3K -$12.5K -241 -71%
SFG
22
SNS Financial Group
Minnesota
$4.3K – – –
TRCT
23
Tower Research Capital (TRC)
New York
$1K +$881 +17 +850%
Osaic Holdings
24
Osaic Holdings
Arizona
$979 – – –
SC
25
Stephens Consulting
Michigan
$645 – – –
1
2

AIM Hedge Fund Activity: Q1 2023 in Review

31 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in AIM ImmunoTech (AIM) for Q1 2023, worth a combined $2.05M — up 23% from $1.67M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of AIM and 1 opened new positions — a net loss of 4 holders — while 7 trimmed existing stakes and 4 added.

The largest buyer was Renaissance Technologies, adding an estimated $16.5K. The largest seller was Morgan Stanley, cutting an estimated $159K.

  • 31 institutional investors held AIM ImmunoTech (AIM) as of Q1 2023, down from 35 in Q4 2022.
  • Funds reported $2.05M of AIM ImmunoTech stock for Q1 2023, up 23% quarter-over-quarter.
  • 1 fund opened new AIM ImmunoTech positions in Q1 2023 and 5 closed out, a net change of -4 holders.
  • The largest AIM ImmunoTech buyer in Q1 2023 was Renaissance Technologies, an estimated $16.5K added.
  • The largest AIM ImmunoTech seller in Q1 2023 was Morgan Stanley, an estimated $159K sold.

Based on aggregated 13F filings for Q1 2023.